Copertina

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xiaohui Wang, Hengqi Liu, Yue Fei, Zheng Song, Xiangrui Meng, Jingwei Yu, Xia Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Early Detection and Central Nervous System Prophylaxis in Patients With High‐Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis
di: Bingyi Wang, et al.
Pubblicazione: (2025)

Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma
di: Yaoli Cui, et al.
Pubblicazione: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
di: Ganggang Wang, et al.
Pubblicazione: (2025)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
di: Fenghua Gao, et al.
Pubblicazione: (2025)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
di: Jiangfang Feng, et al.
Pubblicazione: (2024)

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
di: Evgenia Verrou, et al.
Pubblicazione: (2024)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
di: Beatrice Casadei, et al.
Pubblicazione: (2024)

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
di: Kaitlin Annunzio, et al.
Pubblicazione: (2024)

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan
di: Kenji Ishitsuka, et al.
Pubblicazione: (2024)

Characterizing second line and beyond therapies for primary central nervous system lymphomas
di: Brian Primeaux, et al.
Pubblicazione: (2024)

New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
di: Maria Anele Romeo, et al.
Pubblicazione: (2024)

Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition
di: João L. Pereira, et al.
Pubblicazione: (2024)

The RAS‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group
di: Xinyu Li, et al.
Pubblicazione: (2024)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
di: Elisabetta M. Abenavoli, et al.
Pubblicazione: (2024)

The role of baseline 2‐[ 18 F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis
di: Domenico Albano, et al.
Pubblicazione: (2024)

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
di: Antonio Pinto, et al.
Pubblicazione: (2024)

547 | A PROSPECTIVE MULTICENTER STUDY OF FCR ALTERNATING WITH IBRUTINIB IN TREATMENT‐NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
di: T. Wang, et al.
Pubblicazione: (2025)

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
di: Carmen Martínez, et al.
Pubblicazione: (2024)

Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
di: Mohammed Zuber, et al.
Pubblicazione: (2024)

Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
di: José Carlos Jaime‐Pérez, et al.
Pubblicazione: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
di: Hidehiro Itonaga, et al.
Pubblicazione: (2024)

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
di: Caroline Le Lan, et al.
Pubblicazione: (2024)

586 | OBINUTUZUMAB COMBINED WITH BENDAMUSTINE IN THE TREATMENT OF MATURE B‐CELL LYMPHOMA: AN OPEN‐LABEL, MULTICENTER STUDY
di: Y. Yan, et al.
Pubblicazione: (2025)

698 | A NOVEL PROGNOSTIC MODEL FOR PREDICTING DISEASE PROGRESSION AND SURVIVAL IN PRIMARY LARGE B‐CELL LYMPHOMA OF IMMUNE‐PRIVILEGED SITES
di: G. Wang, et al.
Pubblicazione: (2025)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
di: Hazim S. Ababneh, et al.
Pubblicazione: (2024)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
di: Fuli Fan, et al.
Pubblicazione: (2025)

604 | POLATUZUMAB VEDOTIN AS AN EFFECTIVE SALVAGE THERAPY FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RESISTANTANCE TO BTK AND BCL INHIBITORS
di: P. Yang, et al.
Pubblicazione: (2025)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
di: A. Zduniak, et al.
Pubblicazione: (2024)

Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study
di: Anna Panovská, et al.
Pubblicazione: (2024)

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203
di: Takashi Watanabe, et al.
Pubblicazione: (2024)

750 | GOLIDOCITINIB MONOTHERAPY IN THE TREATMENT OF REFRACTORY/RELAPSED INDOLENT T/NK‐CELL LYMPHOMA: PRELIMINARY RESULTS FROM T‐LGLL COHORT
di: Y. Yu, et al.
Pubblicazione: (2025)

710 | FIRST‐LINE R‐MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PCNSL
di: Z. Li, et al.
Pubblicazione: (2025)

748 | EFFECTIVENESS AND SAFETY OF LINPERLISIB IN PATIENTS WITH MATURE T/NK‐CELL LYMPHOMA: A REAL‐WORLD RETROSPECTIVE STUDY
di: Z. Li, et al.
Pubblicazione: (2025)

490 | MOLECULAR LANDSCAPE OF DISTINCT FOLLICULAR LYMPHOMA HISTOLOGIC GRADES: INSIGHTS FROM GENOMIC AND TRANSCRIPTOME ANALYSES
di: C. Sun, et al.
Pubblicazione: (2025)

Real‐World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15‐Year Period
di: Xue Yang, et al.
Pubblicazione: (2025)

638 | IMPACT OF FIRST‐LINE SETTING MAINTENANCE THERAPY ON PROGNOSIS IN DIFFUSE LARGE B‐CELL LYMPHOMA: A MULTICENTER RETROSPECTIVE STUDY
di: L. Lyu, et al.
Pubblicazione: (2025)

589 | THE EFFICACY AND SAFETY OF ORELABRUTINIB‐BASED REGIMENS IN THE TREATMENT OF MARGINAL ZONE LYMPHOMA: A RETROSPECTIVE REAL‐WORLD STUDY
di: H. Li, et al.
Pubblicazione: (2025)

655 | POLA‐R‐CHP PERFORMED WELL IN POLARIX TRIAL‐INELIGIBLE AND LOW RISK (IPI 0–1) PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: A PROSPECTIVE OBSERVATIONAL STUDY
di: Y. Ren, et al.
Pubblicazione: (2025)

642 | REAL‐WORLD EFFICACY AND SAFETY OF GLOFITAMAB IN CHINESE PATIENTS WITH R/R DLBCL: HIGH RESPONSE RATES IN HIGH‐RISK POPULATIONS
di: Z. Qian, et al.
Pubblicazione: (2025)

704 | ORELABRUTINIB PLUS RITUXIMAB AND HIGH‐DOSE METHOTREXATE IN PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSED LARGE B‐CELL LYMPHOMA: A SINGLE‐ARM PHASE II STUDY
di: F. Zhu, et al.
Pubblicazione: (2025)